Drug Profile

Fosfomycin+metronidazole+molgramostim - Reponex Pharmaceuticals

Alternative Names: RNX-011

Latest Information Update: 08 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Reponex Pharmaceuticals
Class Anti-infectives; Anti-inflammatories; Antibacterials; Antibronchitics; Antifibrotics; Antiprotozoals; Chemoprotectants; Epoxy compounds; Nitroimidazoles; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Radiosensitisers; Recombinant proteins; Skin disorder therapies; Small molecules
Mechanism of Action Cell wall inhibitors; DNA synthesis inhibitors; Granulocyte macrophage colony stimulating factor replacements; Peptidoglycan inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

14 Oct 2022 Fosfomycin+metronidazole+molgramostim is still in phase II trials for peritonitis in Denmark (Reponex Pharmaceuticals, October 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com